The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Diagnosis and treatment of multidrug-resistant tuberculosis
Open accessAbstract
Tuberculosis (TB) is still a major health problem worldwide. Especially, multidrug-resistant TB (MDR-TB), which is defined as TB that shows resistance to both isoniazid and rifampicin, is a barrier in the treatment of TB. Globally, approximately 3.4% of new TB patients and 20% of the patients with a history of previous treatment for TB were diagnosed with MDR-TB. The treatment of MDR-TB requires medications for a long duration (up to 20-24 months) with less effective and toxic second-line drugs and has unfavorable outcomes. However, treatment outcomes are expected to improve due to the introduction of a new agent (bedaquiline), repurposed drugs (linezolid, clofazimine, and cycloserine), and technological advancement in rapid drug sensitivity testing. The World Health Organization (WHO) released a rapid communication in 2018, followed by consolidated guidelines for the treatment of MDR-TB in 2019 based on clinical trials and an individual patient data meta-analysis. In these guidelines, the WHO suggested reclassification of second-line anti-TB drugs and recommended oral treatment regimens that included the new and repurposed agents. The aims of this article are to review the treatment strategies of MDR-TB based on the 2019 WHO guidelines regarding the management of MDR-TB and the diagnostic techniques for detecting resistance, including phenotypic and molecular drug sensitivity tests.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment typically involves standard antitubercular therapy, which is effective in most cases, although multidrug-resistant TB can complicate treatment [32,33,34].”
From Head and Neck Tuberculosis: A Rare Diagnosis and the Role of Surgical Biopsy and Histopathological Evaluation in Extrapulmonary Disease (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Falzon, D., Jaramillo, E., Schünemann, H. J., Arentz, M., Bauer, M., Bayona, J. N., Blanc, L., Caminero, J. A., Daley, C. L., Duncombe, C. J., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00073611 · Cited by 1,098
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Diacon, A. H., Pym, A. S., Grobusch, M. P., Patientia, R. F., Rustomjee, R., Page‐Shipp, L., Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808427 · Cited by 841
Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., Shimokawa, Y., & Komatsu, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030466 · Cited by 752
Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline
Diacon, A. H., Pym, A. S., Grobusch, M. P., Ríos, J. D. L., Gotuzzo, E., Vasilyeva, I. A., Leimane, V., Andries, K., Bakare, N., Marez, T. D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313865 · Cited by 751
Dorman, S. E., Schumacher, S. G., Alland, D., Nabeta, P., Armstrong, D. T., King, B., Hall, S. L., Chakravorty, S., Cirillo, D. M., Tukvadze, N., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30691-6 · Cited by 705
Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Deun, A. V., Maug, A. K. J., Salim, M. A. H., Das, P. K., Sarker, M. R., Daru, P., & Rieder, H. L. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0077oc · Cited by 646
Ahmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31644-1 · Cited by 634
Diarylquinolines target subunit c of mycobacterial ATP synthase
Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio884 · Cited by 547
MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE.
(1963) · Europe PMC (PubMed Central) · Cited by 532
Denkinger, C. M., Schumacher, S. G., Boehme, C. C., Dendukuri, N., Pai, M., & Steingart, K. R. (2014) · European Respiratory Journal · doi:10.1183/09031936.00007814 · Cited by 527 · cited 2×
“A recent study reported that Xpert Ultra was not superior to Xpert in diagnosing tuberculous meningitis [26].”
Background
Research works printed but not linked: 14
- 2018, Global Health Estimates 2016: deaths by cause, age, sex, by country and by region, 2000-2016 [Internet]
- 2019, WHO consolidated guidelines on drug-resistant tuberculosis treatment [Internet]
- 2015, Global tuberculosis report 2015. 20th ed [Internet]
- 2019, Global tuberculosis report 2019 [Internet]
- 2016, Treatment guidelines for drug-resistant tuberculosis, 2016 update [Internet]
- 2009, Guidelines for surveillance of drug resistance in tuberculosis. 4th ed [Internet]
- 2007, Use of liquid TB culture and drug susceptibility testing (DST) in low and medium income setting. Summary report of the Expert Group Meeting on the use of liquid culture media [Internet]
- 2008, Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB) [Internet]
- 2016, The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin [Internet]
- 2020, WHO consolidated guidelines on tuberculosis. Module 3: diagnosis–rapid diagnostics for tuberculosis detection [Internet]
- 2008, GenoType MTBDRplus, ver. 2.0. Instructions for use (IFU-304A-06) [Internet]
- 2020, Molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB and rifampicin resistance in adults and children: rapid communication [Internet]
- 2018, The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide [Internet]
- 2011, Rapid communication: key changes to treatment of multidrug‐ and rifampicin‐resistant tuberculosis (MDR/RR‐TB) [Internet]
Cited by
Sorted by citations
Mancuso, G., Midiri, A., Gaetano, S. D., Ponzo, E., & Biondo, C. (2023) · Microorganisms · doi:10.3390/microorganisms11092277 · Cited by 95
Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies
Kumar, M., Virmani, T., Kumar, G., Deshmukh, R., Sharma, A., Duarte, S. O. D., Brandão, P., & Fonte, P. (2023) · Pharmaceuticals · doi:10.3390/ph16101360 · Cited by 87
Treatment of Human Babesiosis: Then and Now
Renard, I., & Mamoun, C. B. (2021) · Pathogens · doi:10.3390/pathogens10091120 · Cited by 61
Evolution of tuberculosis diagnostics: From molecular strategies to nanodiagnostics
Mukherjee, S., Perveen, S., Negi, A., & Sharma, R. (2023) · Tuberculosis · doi:10.1016/j.tube.2023.102340 · Cited by 69
Omoteso, O. A., Fadaka, A. O., Walker, R. B., & Khamanga, S. M. (2025) · Microorganisms · doi:10.3390/microorganisms13040722 · Cited by 65
Metadata
- Authors
- Jang, J. G., & Chung, J. H.
- Affiliations
- Yeungnam University Medical Center (KR)
- Corresponding author
- Chung, Jin Hong
- Venue
- Yeungnam University Journal of Medicine
- Published
- 2020-10-31
- Volume
- 37
- Issue
- 4
- Pages
- 277-285
- ISSN
- 1225-7737 (ISSN-L)
- 2384-0293
- PMC
- PMC7606956
- OpenAlex
- W3083676524
- Cited by
- 140
- References
- 46
- Citations by year
- 2026: 15 · 2025: 36 · 2024: 42 · 2023: 30 · 2022: 7 · 2021: 9 · 2020: 1
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Journal of Yeungnam Medical Science (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Infectious Diseases › Diagnosis and treatment of tuberculosis
- Keywords
- multidrug-resistant tuberculosis, isoniazid resistance, rifampicin resistance, second-line antituberculosis drugs, bedaquiline, linezolid, clofazimine, cycloserine, drug repurposing, phenotypic drug susceptibility testing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
